Matching articles for "Clear Eyes"

Treatment of Allergic Rhinitis and Allergic Conjunctivitis

   
The Medical Letter on Drugs and Therapeutics • March 31, 2025;  (Issue 1725)
Initial treatment of allergic rhinitis (AR) depends on the severity of symptoms and whether they are intermittent or persistent (see Table...
Initial treatment of allergic rhinitis (AR) depends on the severity of symptoms and whether they are intermittent or persistent (see Table 1).
Med Lett Drugs Ther. 2025 Mar 31;67(1725):49-56 | Show Full IntroductionHide Full Introduction

Drugs for Allergic Rhinitis and Allergic Conjunctivitis

   
The Medical Letter on Drugs and Therapeutics • April 19, 2021;  (Issue 1622)
The choice of drugs for treatment of allergic rhinitis depends on the severity of symptoms and whether they are intermittent or persistent (see Table...
The choice of drugs for treatment of allergic rhinitis depends on the severity of symptoms and whether they are intermittent or persistent (see Table 1).
Med Lett Drugs Ther. 2021 Apr 19;63(1622):57-64 | Show Full IntroductionHide Full Introduction

Cetirizine Ophthalmic Solution (Zerviate) for Allergic Conjunctivitis

   
The Medical Letter on Drugs and Therapeutics • June 1, 2020;  (Issue 1599)
A 0.24% ophthalmic solution of the second-generation H1-antihistamine cetirizine (Zerviate – Eyevance) is now available by prescription for treatment of ocular itching associated with allergic...
A 0.24% ophthalmic solution of the second-generation H1-antihistamine cetirizine (Zerviate – Eyevance) is now available by prescription for treatment of ocular itching associated with allergic conjunctivitis in patients ≥2 years old. Oral cetirizine (Zyrtec, and others), which is used for treatment of allergic conjunctivitis and rhinitis, has been available over the counter (OTC) for years.
Med Lett Drugs Ther. 2020 Jun 1;62(1599):81-3 | Show Full IntroductionHide Full Introduction

OTC Brimonidine (Lumify) for Ocular Redness

   
The Medical Letter on Drugs and Therapeutics • October 22, 2018;  (Issue 1558)
The FDA has approved an over-the-counter (OTC) 0.025% ophthalmic formulation of the selective alpha2-adrenergic agonist brimonidine tartrate (Lumify – Bausch & Lomb) for treatment of ocular redness...
The FDA has approved an over-the-counter (OTC) 0.025% ophthalmic formulation of the selective alpha2-adrenergic agonist brimonidine tartrate (Lumify – Bausch & Lomb) for treatment of ocular redness in adults and children ≥5 years old. Lumify is the first brimonidine product to be approved for OTC use.
Med Lett Drugs Ther. 2018 Oct 22;60(1558):176 | Show Full IntroductionHide Full Introduction